Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Sept 2022

Li Fuyang, Bondra Kathryn M, Ghilu Samson, Studebaker Adam, Liu Qianqian, Michalek Joel E, Kogiso Mari, Li Xiao-Nan, Kalapurakal John A, James C David, Burma Sandeep, Kurmasheva Raushan T, Houghton Peter J

Abstract excerpt

PURPOSE: We investigated why three patient-derived xenograft (PDX) childhood BRAFV600E-mutant brain tumor models are highly sensitive to trametinib. Mechanisms of acquired resistance selected in situ, and approaches to prevent resistance were also examined, which may translate to both low-grade glioma (LGG) molecular subtypes. EXPERIMENTAL DESIGN: Sensitivity to trametinib [MEK inhibitor (MEKi)] alone or in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mechanistic Target of Rapamycin Complex 1

Share to Mitogen-Activated Protein Kinase Kinases

Share to Proto-Oncogene Proteins B-raf

Share to Pyridones

Share to Pyrimidinones

Share to Sirolimus

Source

Open in PubMed Open full text

Identifiers

PMID: 35797217
DOI: 10.1158/1078-0432.CCR-22-1052
PMCID: PMC10230442

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models.PMID 35797217Read ↗

Dual inhibition of MAPK and TORC1 signaling retards development of radiation resistance in pediatric BRAFV600E glioma models.Semantic proximity Read ↗

Co-targeting CDK4/6 and MEK reverses mesenchymal transition in therapy-refractory BRAF-altered pediatric high-grade glioma.Semantic proximity Read ↗

Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumorsSemantic proximity Read ↗

A High-Throughput In Vitro Drug Screen in a Genetically Engineered Mouse Model of Diffuse Intrinsic Pontine Glioma Identifies BMS-754807 as a Promising Therapeutic AgentSemantic proximity Read ↗

Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations.Semantic proximity Read ↗

ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse modelsSemantic proximity Read ↗

ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse modelsSemantic proximity Read ↗

Resistance mechanisms in BRAFV600E paediatric high-grade glioma and current therapeutic approachesSemantic proximity Read ↗

Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma.Semantic proximity Read ↗

Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine gliomaSemantic proximity Read ↗

Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.Semantic proximity Read ↗

Targeted Therapy Win in BRAF-Mutant Gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.